Triggering Receptor Expressed on Myeloid Cells-2 Expression Tracks With M2-Like Macrophage Activity and Disease Severity in COPD

Chest

Volumn 153, Issue 1, 2018, Pages 77-86

  Byers, Derek E ^a   Wu, Kangyun ^a   Dang Vu, Geoffrey ^b   Jin, Xiaohua ^a   Agapov, Eugene ^a   Zhang, Xiaofeng ^a   Battaile, John T ^c   Schechtman, Kenneth ^a   Yusen, Roger ^a   Pierce, Richard A ^a   Holtzman, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

COPD; macrophages; translating basic research; Triggering Receptor Expressed on Myeloid Cells 2; type 2 inflammation

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR2; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; MESSENGER RNA; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; BETA N ACETYLHEXOSAMINIDASE; CD68 ANTIGEN, HUMAN; CHITOTRIOSIDASE; DIFFERENTIATION ANTIGEN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TREM1 PROTEIN, HUMAN; TREM2 PROTEIN, HUMAN; TYROBP PROTEIN, HUMAN;

ADULT; ARTICLE; BONE MARROW CELL; CHIT1 GENE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE EXACERBATION; LUNG ALVEOLUS MACROPHAGE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; VITAL CAPACITY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HEXOSAMINIDASES; HUMANS; MACROPHAGES, ALVEOLAR; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; MYELOID CELLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1; VITAL CAPACITY;

EID: 85040181915     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.09.044     Document Type: Article

References (31)

1. World Health Organization. Chronic respiratory diseases. http://www.who.int/respiratory/copd/burden/en/. Accessed April 4, 2017.
2. Faner, R., Tal-Singer, R., Riley, J.H., et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 69:7 (2014), 666–672.
3. Holtzman, M.J., Byers, D.E., Alexander-Brett, J., Wang, X., The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat Rev Immunol 14:10 (2014), 686–698.
4. Holtzman, M.J., Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. J Clin Invest 122:8 (2012), 2741–2748.
5. Fahy, J.V., Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol 15:1 (2015), 57–65.
6. Kim, E.Y., Battaile, J.T., Patel, A.C., et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 14:6 (2008), 633–640.
7. Byers, D.E., Alexander-Brett, J., Patel, A.C., et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123:9 (2013), 3967–3982.
8. Tyner, J.W., Kim, E.Y., Ide, K., et al. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest 116:2 (2006), 309–321.
9. Agapov, E., Battaile, J.T., Tidwell, R., et al. Macrophage chitinase 1 stratifies chronic obstructive lung disease. Am J Respir Cell Mol Biol 41:4 (2009), 379–384.
10. Alevy, Y.G., Patel, A.C., Romero, A.G., et al. IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. J Clin Invest 122:12 (2012), 4555–4568.
11. Shang, J., Zhao, J., Wu, X., Xu, Y., Xie, J., Zhao, J., Interleukin-33 promotes inflammatory cytokine production in chronic airway inflammation. Biochem Cell Biol 93:4 (2015), 359–366.
12. Shaykhiev, R., Krause, A., Salit, J., et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol 183:4 (2009), 2867–2883.
13. Bouchon, A., Facchetti, F., Weigand, M.A., Colonna, M., TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410:6832 (2001), 1103–1107.
14. Jiyong, J., Tiancha, H., Wei, C., Huahao, S., Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive Care Med 35:4 (2009), 587–595.
15. Gibot, S., Kolopp-Sarda, M.N., Bene, M.C., et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 141:1 (2004), 9–15.
16. Gibot, S., Cravoisy, A., Levy, B., Bene, M.C., Faure, G., Bollaert, P.E., Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 350:5 (2004), 451–458.
17. Turnbull, I.R., Gilfillan, S., Cella, M., et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177:6 (2006), 3520–3524.
18. Wu, K., Byers, D.E., Jin, X., et al. TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. J Exp Med 212:5 (2015), 681–697.
19. Byers, D.E., Holtzman, M.J., Alternatively activated macrophages and airway disease. Chest 140:3 (2011), 768–774.
20. Piccio, L., Buonsanti, C., Cella, M., et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain: A Journal of Neurology 131:Pt 11 (2008), 3081–3091.
21. Kleinberger, G., Yamanishi, Y., Suarez-Calvet, M., et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med, 6(243), 2014, 243ra286.
22. Rohde, G., Radsak, M.P., Borg, I., Buhl, R., Schultze-Werninghaus, G., Taube, C., Levels of soluble triggering receptor expressed on myeloid cells 1 in infectious exacerbations of chronic obstructive pulmonary disease. Respiration 83:2 (2012), 133–139.
23. Radsak, M.P., Taube, C., Haselmayer, P., et al. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin Dev Immunol, 2007, 2007, 52040.
24. Phua, J., Koay, E.S., Zhang, D., et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J 28:4 (2006), 695–702.
25. Woodruff, P.G., Koth, L.L., Yang, Y.H., et al. A distinctive alveolar macrophage activation state induced by cigarette smoking. Am J Respir Crit Care Med 172:11 (2005), 1383–1392.
26. Koth, L.L., Cambier, C.J., Ellwanger, A., et al. DAP12 is required for macrophage recruitment to the lung in response to cigarette smoke and chemotaxis toward CCL2. J Immunol 184:11 (2010), 6522–6528.
27. Dang-Vu, G., Wu, K., Jin, X., et al. Trem-2/trem-1 imbalance reflects alternative (m2) macrophage activation and disease severity in COPD. Am J Respir Crit Care Med, 187, 2013, A4141.
28. Barrow, A.D., Palarasah, Y., Bugatti, M., et al. OSCAR is a receptor for surfactant protein D that activates TNF-alpha release from human CCR2+ inflammatory monocytes. J Immunol 194:7 (2015), 3317–3326.
29. Hoenderdos, K., Condliffe, A., The neutrophil in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 48:5 (2013), 531–539.
30. Sharif, O., Knapp, S., From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213:9-10 (2008), 701–713.
31. Piccio, L., Deming, Y., Del-Aguila, J.L., et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131:6 (2016), 925–933.